In this video, I will talk about TransMedics (NASDAQ: TMDX) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating TransMedics Group, Inc. (Nasdaq: TMDX) for potential securities law violations. Investors who have lost money in their ...

Despite a Q3 revenue miss and temporary issues, TransMedics' long-term growth prospects remain strong, with plans for ...

Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 15.56% on an annualized basis producing an average ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - January 10, 2025) - Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc.

As substantial as TransMedics' stock sell-off has been, its underlying business is by no means 63% worse. As we keep our gaze ...

TransMedics Group Inc (TMDX) stock saw a decline, ending the day at $72.55 which represents a decrease of $-6.12 or -7.78% from the prior close of $78.67. The stock opened at $75.81 and touched a low ...